DE602004024988D1 - 2-aminopyrimidin-derivate als raf-kinase-hemmer - Google Patents

2-aminopyrimidin-derivate als raf-kinase-hemmer

Info

Publication number
DE602004024988D1
DE602004024988D1 DE602004024988T DE602004024988T DE602004024988D1 DE 602004024988 D1 DE602004024988 D1 DE 602004024988D1 DE 602004024988 T DE602004024988 T DE 602004024988T DE 602004024988 T DE602004024988 T DE 602004024988T DE 602004024988 D1 DE602004024988 D1 DE 602004024988D1
Authority
DE
Germany
Prior art keywords
raf kinase
sub
kinase inhibitors
aminopyrimidine derivatives
phenyl radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004024988T
Other languages
English (en)
Inventor
David Bryant Batt
Timothy Michael Ramsey
Michael Lloyd Sabio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602004024988D1 publication Critical patent/DE602004024988D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE602004024988T 2003-06-13 2004-06-11 2-aminopyrimidin-derivate als raf-kinase-hemmer Active DE602004024988D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47870903P 2003-06-13 2003-06-13
PCT/EP2004/006317 WO2004110452A1 (en) 2003-06-13 2004-06-11 2-aminopyrimidine derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602004024988D1 true DE602004024988D1 (de) 2010-02-25

Family

ID=33551850

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024988T Active DE602004024988D1 (de) 2003-06-13 2004-06-11 2-aminopyrimidin-derivate als raf-kinase-hemmer

Country Status (14)

Country Link
US (1) US20060293340A1 (de)
EP (1) EP1635835B1 (de)
JP (1) JP2006527230A (de)
CN (1) CN1805748B (de)
AT (1) ATE454152T1 (de)
AU (1) AU2004246800B2 (de)
BR (1) BRPI0411365A (de)
CA (1) CA2529090A1 (de)
DE (1) DE602004024988D1 (de)
ES (1) ES2338557T3 (de)
MX (1) MXPA05013349A (de)
PL (1) PL1635835T3 (de)
PT (1) PT1635835E (de)
WO (1) WO2004110452A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
AP2470A (en) 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
US20080207658A1 (en) * 2005-02-25 2008-08-28 Manley Paul W Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
US8168787B2 (en) 2006-11-16 2012-05-01 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the preparation of imatinib and intermediates thereof
EP2152688A1 (de) * 2007-05-04 2010-02-17 Irm Llc Verbindungen und zusammensetzungen als c-kit- und pdgfr-kinasehemmer
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
WO2008153959A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
JP5511680B2 (ja) 2007-12-19 2014-06-04 キャンサー・リサーチ・テクノロジー・リミテッド ピリド[2,3−b]ピラジン−8−置換化合物及びその使用
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2265608A2 (de) * 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
TW200940539A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
JP2013526513A (ja) * 2010-05-11 2013-06-24 クリサニ バイオサイエンシーズ プライベート リミッテッド 4,6−ジベンジルアミン−2−メチル−ピリミジン誘導体、および癌治療のためのそれらの使用
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP2013543008A (ja) * 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド Braf阻害剤による治療方法
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2980478C (en) * 2015-04-23 2024-01-23 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases
CN108586439A (zh) * 2018-06-03 2018-09-28 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108610336A (zh) * 2018-06-03 2018-10-02 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108864060A (zh) * 2018-06-03 2018-11-23 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TW202333718A (zh) * 2022-02-03 2023-09-01 美商奈可薩斯醫藥有限公司 芳基烴受體促效劑及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2003070173A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
BRPI0312288B8 (pt) * 2002-06-28 2021-05-25 Nippon Shinyaku Co Ltd derivados de amidas
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts

Also Published As

Publication number Publication date
CA2529090A1 (en) 2004-12-23
AU2004246800A1 (en) 2004-12-23
US20060293340A1 (en) 2006-12-28
WO2004110452A1 (en) 2004-12-23
AU2004246800B2 (en) 2008-12-04
BRPI0411365A (pt) 2006-07-25
MXPA05013349A (es) 2006-03-09
ES2338557T3 (es) 2010-05-10
EP1635835A1 (de) 2006-03-22
ATE454152T1 (de) 2010-01-15
CN1805748A (zh) 2006-07-19
CN1805748B (zh) 2010-05-26
PL1635835T3 (pl) 2010-06-30
JP2006527230A (ja) 2006-11-30
PT1635835E (pt) 2010-03-17
EP1635835B1 (de) 2010-01-06

Similar Documents

Publication Publication Date Title
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
NO20044995L (no) Heterosykliske forbindelser
WO2003051366A3 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
MY140572A (en) Quinazolinone derivatives as parp inhibitors
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EP2205088A4 (de) Auf naphthalin basierende hemmer von anti-apoptotischen proteinen
ATE346067T1 (de) Carbolinderivate
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
NO20044526L (no) Hemisterlinderivater og anvendelser derav
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition